Lineage Cell Therapeutics (LCTX) Retained Earnings (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Retained Earnings of -$471.8 million for Q1 2026, down 17498.28% year-over-year from N/an in Q1 2025, and down 11935.97% quarter-over-quarter from -$3.9 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Retained Earnings (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Retained Earnings history runs 17 years deep, the most recent figure standing at -$471.8 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 17498.28% year-over-year to -$471.8 million; the TTM figure through Mar 2026 stood at -$471.8 million (down 17498.28% YoY), while the FY2025 annual figure was -$3.9 million, down 36.3% from the prior year.
- Retained Earnings for Q1 2026 stood at -$471.8 million, down from -$3.9 million in the prior quarter.
- The five-year high for Retained Earnings was -$2.7 million in Q1 2025, with the low at -$471.8 million in Q1 2026.
- The 5-year median for Retained Earnings is -$363.4 million (2022), against an average of -$253.3 million.
- The sharpest annual moves came in 2024 and 2026: Retained Earnings surged 99.25% in 2024, then tumbled 17498.28% in 2026.
- Lineage Cell Therapeutics' Retained Earnings stood at -$363.4 million in 2022, then declined by 5.91% to -$384.9 million in 2023, then soared by 99.25% to -$2.9 million in 2024, then sank by 36.3% to -$3.9 million in 2025, then slumped by 11935.97% to -$471.8 million in 2026.
- Business Quant data shows LCTX's Retained Earnings at -$471.8 million in Q1 2026, -$3.9 million in Q4 2025, and -$4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | -470.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -470.33 Mn |
| Mar 31, 2026 | -471.81 Mn |
| Dec 31, 2025 | -3.92 Mn |
| Sep 30, 2025 | -4.29 Mn |
| Jun 30, 2025 | -438.07 Mn |
| Mar 31, 2025 | -2.68 Mn |
| Dec 31, 2024 | -2.88 Mn |
| Sep 30, 2024 | -400.19 Mn |
| Jun 30, 2024 | -397.16 Mn |
| Mar 31, 2024 | -2.77 Mn |
| Dec 31, 2023 | -384.86 Mn |
| Sep 30, 2023 | -380.08 Mn |
| Jun 30, 2023 | -372.97 Mn |
| Mar 31, 2023 | -367.74 Mn |
| Dec 31, 2022 | -363.37 Mn |
| Sep 30, 2022 | -357.02 Mn |
| Jun 30, 2022 | -350.95 Mn |
| Mar 31, 2022 | -5.09 Mn |
| Dec 31, 2021 | -5.21 Mn |
| Sep 30, 2021 | -3.43 Mn |